1306. Lower Treatment Failure Rates in Patients with Non-Staphylococcal Prosthetic Joint Infections (PJI) Treated with Debridement and Implant Retention (DAIR) Receiving Chronic Antibiotic Suppression (CAS)

Abstract Background PJI occurs in 0.5-2% of Joint Arthroplasty. Patients with acute non-Staphylococcal PJI who undergo DAIR are treated with 6 weeks of antimicrobials after which CAS may be considered. We aimed to compare the incidence of treatment failure between people who received CAS and those w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open forum infectious diseases 2023-11, Vol.10 (Supplement_2)
Hauptverfasser: Sekar, Poorani, Merchant, James, Alexander, Bruce, Miell, Kelly, Beck, Brice, Nair, Rajeshwari, Suh, Daniel, Richards, Christopher, Puig-Asensio, Mireia, Pugely, Andrew, Walhof, Julia, Dukes, Kimberly, Schweizer, Marin
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_2
container_start_page
container_title Open forum infectious diseases
container_volume 10
creator Sekar, Poorani
Merchant, James
Alexander, Bruce
Miell, Kelly
Beck, Brice
Nair, Rajeshwari
Suh, Daniel
Richards, Christopher
Puig-Asensio, Mireia
Pugely, Andrew
Walhof, Julia
Dukes, Kimberly
Schweizer, Marin
description Abstract Background PJI occurs in 0.5-2% of Joint Arthroplasty. Patients with acute non-Staphylococcal PJI who undergo DAIR are treated with 6 weeks of antimicrobials after which CAS may be considered. We aimed to compare the incidence of treatment failure between people who received CAS and those who did not. Methods This is a retrospective cohort study of patients admitted to Veterans Affairs (VA) hospitals from 2003-2017 with a non-Staphylococcal PJI, underwent DAIR and received 6 weeks of antimicrobial treatment (Table 1). CAS was defined as at least 30 days of oral antibiotics after 6 weeks of antimicrobial treatment. Duration of CAS was categorized as short (1-3 months), moderate (3-6 months) and long ( >6 months) (Fig 1). Patients were followed for 5 years. Treatment failure was defined as microbiologically confirmed recurrent PJI, additional debridement or re-operation at the same site. Cause-specific Kaplan-Meier curves were used to compare treatment failure rates between those who did and did not receive CAS, censoring on death. Results Among 468 patients with non-staphylococcal PJI who underwent DAIR, 208 (44.4%) received CAS. Patients with Enterococcus PJI were statistically more likely to receive CAS. K-M curves showed patients on CAS had a higher estimated failure free survival probability at 5 years when compared to those who did not get CAS (66% vs. 55%, p< 0.01) (Fig 2). When antibiotic use was considered as a time-dependent covariate, CAS was associated with a decreased hazard of treatment failure (hazard ratio (HR): .47 (95% confidence interval [CI]: 0.29, 0.76). After statistically adjusting for surgical site, severity of illness, and alcohol abuse, a short duration of CAS was significantly associated with decreased treatment failure (HR=0.24; 95% CI: 0.11, 0.52). There was no significant association between moderate or long duration of CAS and treatment failure (Table 2) Table 2 Conclusion A short duration of CAS may be beneficial among patients with non-Staphylococcal PJI who underwent DAIR. However, there was not a statistically significant association between longer duration of CAS use and treatment failure. Thus, the risks and benefits of long-term antibiotics should be weighed when aiming to prevent recurrence of PJI. Disclosures Mireia Puig-Asensio, MD, GILEAD: Honoraria Andrew Pugely, MD, MBA, Globus Medical: Advisor/Consultant|Globus Medical: Grant/Research Support|Globus Medical: IP royalties|Medtronic: Advisor/Consultant|Medt
doi_str_mv 10.1093/ofid/ofad500.1145
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ofid_ofad500_1145</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ofid/ofad500.1145</oup_id><sourcerecordid>10.1093/ofid/ofad500.1145</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1225-31bf4031a37e7a64205d9c91dbd7348043e4e80cdd72efe3477368f9c74754993</originalsourceid><addsrcrecordid>eNqNkUFOwzAQRSMEEgg4ADsvqUTAjp06WVaFQlAFVVvWkWNPqFEaR7ZLxSU5E07DgiUbe_Rn_huNfhRdEXxLcE7vTK1VeIRKcVAIS4-is4QmWZzlKT_-U59Gl859YIwJwSnm-Vn0TSge36K52YNFawvCb6H1aCZ0s7OAlsKDQ7pFC-F1aDi0136DXkwbr7zoNl-NkUZK0aCFNc5vwGuJno0OiKKtQXptWoeuF8_FaKCDGgj3UFmt4LBMtAoV264RoV6CD1Jwoev7SbEcBUGC_tTtO5purGkDfhL6lTb9ptWu6yw4d5ifTlaji-ikFo2Dy9__PHqbPaynT_H89bGYTuaxJEmSxpRUNcOUCMqBizFLcKpymRNVKU5ZhhkFBhmWSvEEaqCMczrO6lxyxlOW5_Q8IgNXhrOdhbrsrN4K-1USXPaZlH0m5W8mZZ9J8NwMHrPr_jH-A9T1kVo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1306. Lower Treatment Failure Rates in Patients with Non-Staphylococcal Prosthetic Joint Infections (PJI) Treated with Debridement and Implant Retention (DAIR) Receiving Chronic Antibiotic Suppression (CAS)</title><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sekar, Poorani ; Merchant, James ; Alexander, Bruce ; Miell, Kelly ; Beck, Brice ; Nair, Rajeshwari ; Suh, Daniel ; Richards, Christopher ; Puig-Asensio, Mireia ; Pugely, Andrew ; Walhof, Julia ; Dukes, Kimberly ; Schweizer, Marin</creator><creatorcontrib>Sekar, Poorani ; Merchant, James ; Alexander, Bruce ; Miell, Kelly ; Beck, Brice ; Nair, Rajeshwari ; Suh, Daniel ; Richards, Christopher ; Puig-Asensio, Mireia ; Pugely, Andrew ; Walhof, Julia ; Dukes, Kimberly ; Schweizer, Marin</creatorcontrib><description>Abstract Background PJI occurs in 0.5-2% of Joint Arthroplasty. Patients with acute non-Staphylococcal PJI who undergo DAIR are treated with 6 weeks of antimicrobials after which CAS may be considered. We aimed to compare the incidence of treatment failure between people who received CAS and those who did not. Methods This is a retrospective cohort study of patients admitted to Veterans Affairs (VA) hospitals from 2003-2017 with a non-Staphylococcal PJI, underwent DAIR and received 6 weeks of antimicrobial treatment (Table 1). CAS was defined as at least 30 days of oral antibiotics after 6 weeks of antimicrobial treatment. Duration of CAS was categorized as short (1-3 months), moderate (3-6 months) and long ( &gt;6 months) (Fig 1). Patients were followed for 5 years. Treatment failure was defined as microbiologically confirmed recurrent PJI, additional debridement or re-operation at the same site. Cause-specific Kaplan-Meier curves were used to compare treatment failure rates between those who did and did not receive CAS, censoring on death. Results Among 468 patients with non-staphylococcal PJI who underwent DAIR, 208 (44.4%) received CAS. Patients with Enterococcus PJI were statistically more likely to receive CAS. K-M curves showed patients on CAS had a higher estimated failure free survival probability at 5 years when compared to those who did not get CAS (66% vs. 55%, p&lt; 0.01) (Fig 2). When antibiotic use was considered as a time-dependent covariate, CAS was associated with a decreased hazard of treatment failure (hazard ratio (HR): .47 (95% confidence interval [CI]: 0.29, 0.76). After statistically adjusting for surgical site, severity of illness, and alcohol abuse, a short duration of CAS was significantly associated with decreased treatment failure (HR=0.24; 95% CI: 0.11, 0.52). There was no significant association between moderate or long duration of CAS and treatment failure (Table 2) Table 2 Conclusion A short duration of CAS may be beneficial among patients with non-Staphylococcal PJI who underwent DAIR. However, there was not a statistically significant association between longer duration of CAS use and treatment failure. Thus, the risks and benefits of long-term antibiotics should be weighed when aiming to prevent recurrence of PJI. Disclosures Mireia Puig-Asensio, MD, GILEAD: Honoraria Andrew Pugely, MD, MBA, Globus Medical: Advisor/Consultant|Globus Medical: Grant/Research Support|Globus Medical: IP royalties|Medtronic: Advisor/Consultant|Medtronic: Grant/Research Support|RDB Bioinformatics: Grant/Research Support|United Healthcare: Advisor/Consultant</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofad500.1145</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Sekar, Poorani</creatorcontrib><creatorcontrib>Merchant, James</creatorcontrib><creatorcontrib>Alexander, Bruce</creatorcontrib><creatorcontrib>Miell, Kelly</creatorcontrib><creatorcontrib>Beck, Brice</creatorcontrib><creatorcontrib>Nair, Rajeshwari</creatorcontrib><creatorcontrib>Suh, Daniel</creatorcontrib><creatorcontrib>Richards, Christopher</creatorcontrib><creatorcontrib>Puig-Asensio, Mireia</creatorcontrib><creatorcontrib>Pugely, Andrew</creatorcontrib><creatorcontrib>Walhof, Julia</creatorcontrib><creatorcontrib>Dukes, Kimberly</creatorcontrib><creatorcontrib>Schweizer, Marin</creatorcontrib><title>1306. Lower Treatment Failure Rates in Patients with Non-Staphylococcal Prosthetic Joint Infections (PJI) Treated with Debridement and Implant Retention (DAIR) Receiving Chronic Antibiotic Suppression (CAS)</title><title>Open forum infectious diseases</title><description>Abstract Background PJI occurs in 0.5-2% of Joint Arthroplasty. Patients with acute non-Staphylococcal PJI who undergo DAIR are treated with 6 weeks of antimicrobials after which CAS may be considered. We aimed to compare the incidence of treatment failure between people who received CAS and those who did not. Methods This is a retrospective cohort study of patients admitted to Veterans Affairs (VA) hospitals from 2003-2017 with a non-Staphylococcal PJI, underwent DAIR and received 6 weeks of antimicrobial treatment (Table 1). CAS was defined as at least 30 days of oral antibiotics after 6 weeks of antimicrobial treatment. Duration of CAS was categorized as short (1-3 months), moderate (3-6 months) and long ( &gt;6 months) (Fig 1). Patients were followed for 5 years. Treatment failure was defined as microbiologically confirmed recurrent PJI, additional debridement or re-operation at the same site. Cause-specific Kaplan-Meier curves were used to compare treatment failure rates between those who did and did not receive CAS, censoring on death. Results Among 468 patients with non-staphylococcal PJI who underwent DAIR, 208 (44.4%) received CAS. Patients with Enterococcus PJI were statistically more likely to receive CAS. K-M curves showed patients on CAS had a higher estimated failure free survival probability at 5 years when compared to those who did not get CAS (66% vs. 55%, p&lt; 0.01) (Fig 2). When antibiotic use was considered as a time-dependent covariate, CAS was associated with a decreased hazard of treatment failure (hazard ratio (HR): .47 (95% confidence interval [CI]: 0.29, 0.76). After statistically adjusting for surgical site, severity of illness, and alcohol abuse, a short duration of CAS was significantly associated with decreased treatment failure (HR=0.24; 95% CI: 0.11, 0.52). There was no significant association between moderate or long duration of CAS and treatment failure (Table 2) Table 2 Conclusion A short duration of CAS may be beneficial among patients with non-Staphylococcal PJI who underwent DAIR. However, there was not a statistically significant association between longer duration of CAS use and treatment failure. Thus, the risks and benefits of long-term antibiotics should be weighed when aiming to prevent recurrence of PJI. Disclosures Mireia Puig-Asensio, MD, GILEAD: Honoraria Andrew Pugely, MD, MBA, Globus Medical: Advisor/Consultant|Globus Medical: Grant/Research Support|Globus Medical: IP royalties|Medtronic: Advisor/Consultant|Medtronic: Grant/Research Support|RDB Bioinformatics: Grant/Research Support|United Healthcare: Advisor/Consultant</description><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><recordid>eNqNkUFOwzAQRSMEEgg4ADsvqUTAjp06WVaFQlAFVVvWkWNPqFEaR7ZLxSU5E07DgiUbe_Rn_huNfhRdEXxLcE7vTK1VeIRKcVAIS4-is4QmWZzlKT_-U59Gl859YIwJwSnm-Vn0TSge36K52YNFawvCb6H1aCZ0s7OAlsKDQ7pFC-F1aDi0136DXkwbr7zoNl-NkUZK0aCFNc5vwGuJno0OiKKtQXptWoeuF8_FaKCDGgj3UFmt4LBMtAoV264RoV6CD1Jwoev7SbEcBUGC_tTtO5purGkDfhL6lTb9ptWu6yw4d5ifTlaji-ikFo2Dy9__PHqbPaynT_H89bGYTuaxJEmSxpRUNcOUCMqBizFLcKpymRNVKU5ZhhkFBhmWSvEEaqCMczrO6lxyxlOW5_Q8IgNXhrOdhbrsrN4K-1USXPaZlH0m5W8mZZ9J8NwMHrPr_jH-A9T1kVo</recordid><startdate>20231127</startdate><enddate>20231127</enddate><creator>Sekar, Poorani</creator><creator>Merchant, James</creator><creator>Alexander, Bruce</creator><creator>Miell, Kelly</creator><creator>Beck, Brice</creator><creator>Nair, Rajeshwari</creator><creator>Suh, Daniel</creator><creator>Richards, Christopher</creator><creator>Puig-Asensio, Mireia</creator><creator>Pugely, Andrew</creator><creator>Walhof, Julia</creator><creator>Dukes, Kimberly</creator><creator>Schweizer, Marin</creator><general>Oxford University Press</general><scope>TOX</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20231127</creationdate><title>1306. Lower Treatment Failure Rates in Patients with Non-Staphylococcal Prosthetic Joint Infections (PJI) Treated with Debridement and Implant Retention (DAIR) Receiving Chronic Antibiotic Suppression (CAS)</title><author>Sekar, Poorani ; Merchant, James ; Alexander, Bruce ; Miell, Kelly ; Beck, Brice ; Nair, Rajeshwari ; Suh, Daniel ; Richards, Christopher ; Puig-Asensio, Mireia ; Pugely, Andrew ; Walhof, Julia ; Dukes, Kimberly ; Schweizer, Marin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1225-31bf4031a37e7a64205d9c91dbd7348043e4e80cdd72efe3477368f9c74754993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sekar, Poorani</creatorcontrib><creatorcontrib>Merchant, James</creatorcontrib><creatorcontrib>Alexander, Bruce</creatorcontrib><creatorcontrib>Miell, Kelly</creatorcontrib><creatorcontrib>Beck, Brice</creatorcontrib><creatorcontrib>Nair, Rajeshwari</creatorcontrib><creatorcontrib>Suh, Daniel</creatorcontrib><creatorcontrib>Richards, Christopher</creatorcontrib><creatorcontrib>Puig-Asensio, Mireia</creatorcontrib><creatorcontrib>Pugely, Andrew</creatorcontrib><creatorcontrib>Walhof, Julia</creatorcontrib><creatorcontrib>Dukes, Kimberly</creatorcontrib><creatorcontrib>Schweizer, Marin</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>CrossRef</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sekar, Poorani</au><au>Merchant, James</au><au>Alexander, Bruce</au><au>Miell, Kelly</au><au>Beck, Brice</au><au>Nair, Rajeshwari</au><au>Suh, Daniel</au><au>Richards, Christopher</au><au>Puig-Asensio, Mireia</au><au>Pugely, Andrew</au><au>Walhof, Julia</au><au>Dukes, Kimberly</au><au>Schweizer, Marin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1306. Lower Treatment Failure Rates in Patients with Non-Staphylococcal Prosthetic Joint Infections (PJI) Treated with Debridement and Implant Retention (DAIR) Receiving Chronic Antibiotic Suppression (CAS)</atitle><jtitle>Open forum infectious diseases</jtitle><date>2023-11-27</date><risdate>2023</risdate><volume>10</volume><issue>Supplement_2</issue><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract Background PJI occurs in 0.5-2% of Joint Arthroplasty. Patients with acute non-Staphylococcal PJI who undergo DAIR are treated with 6 weeks of antimicrobials after which CAS may be considered. We aimed to compare the incidence of treatment failure between people who received CAS and those who did not. Methods This is a retrospective cohort study of patients admitted to Veterans Affairs (VA) hospitals from 2003-2017 with a non-Staphylococcal PJI, underwent DAIR and received 6 weeks of antimicrobial treatment (Table 1). CAS was defined as at least 30 days of oral antibiotics after 6 weeks of antimicrobial treatment. Duration of CAS was categorized as short (1-3 months), moderate (3-6 months) and long ( &gt;6 months) (Fig 1). Patients were followed for 5 years. Treatment failure was defined as microbiologically confirmed recurrent PJI, additional debridement or re-operation at the same site. Cause-specific Kaplan-Meier curves were used to compare treatment failure rates between those who did and did not receive CAS, censoring on death. Results Among 468 patients with non-staphylococcal PJI who underwent DAIR, 208 (44.4%) received CAS. Patients with Enterococcus PJI were statistically more likely to receive CAS. K-M curves showed patients on CAS had a higher estimated failure free survival probability at 5 years when compared to those who did not get CAS (66% vs. 55%, p&lt; 0.01) (Fig 2). When antibiotic use was considered as a time-dependent covariate, CAS was associated with a decreased hazard of treatment failure (hazard ratio (HR): .47 (95% confidence interval [CI]: 0.29, 0.76). After statistically adjusting for surgical site, severity of illness, and alcohol abuse, a short duration of CAS was significantly associated with decreased treatment failure (HR=0.24; 95% CI: 0.11, 0.52). There was no significant association between moderate or long duration of CAS and treatment failure (Table 2) Table 2 Conclusion A short duration of CAS may be beneficial among patients with non-Staphylococcal PJI who underwent DAIR. However, there was not a statistically significant association between longer duration of CAS use and treatment failure. Thus, the risks and benefits of long-term antibiotics should be weighed when aiming to prevent recurrence of PJI. Disclosures Mireia Puig-Asensio, MD, GILEAD: Honoraria Andrew Pugely, MD, MBA, Globus Medical: Advisor/Consultant|Globus Medical: Grant/Research Support|Globus Medical: IP royalties|Medtronic: Advisor/Consultant|Medtronic: Grant/Research Support|RDB Bioinformatics: Grant/Research Support|United Healthcare: Advisor/Consultant</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/ofid/ofad500.1145</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2328-8957
ispartof Open forum infectious diseases, 2023-11, Vol.10 (Supplement_2)
issn 2328-8957
2328-8957
language eng
recordid cdi_crossref_primary_10_1093_ofid_ofad500_1145
source DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central
title 1306. Lower Treatment Failure Rates in Patients with Non-Staphylococcal Prosthetic Joint Infections (PJI) Treated with Debridement and Implant Retention (DAIR) Receiving Chronic Antibiotic Suppression (CAS)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T09%3A32%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1306.%20Lower%20Treatment%20Failure%20Rates%20in%20Patients%20with%20Non-Staphylococcal%20Prosthetic%20Joint%20Infections%20(PJI)%20Treated%20with%20Debridement%20and%20Implant%20Retention%20(DAIR)%20Receiving%20Chronic%20Antibiotic%20Suppression%20(CAS)&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Sekar,%20Poorani&rft.date=2023-11-27&rft.volume=10&rft.issue=Supplement_2&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofad500.1145&rft_dat=%3Coup_cross%3E10.1093/ofid/ofad500.1145%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/ofid/ofad500.1145&rfr_iscdi=true